Literature DB >> 9303359

Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients.

P Cariuk1, M J Lorite, P T Todorov, W N Field, S J Wigmore, M J Tisdale.   

Abstract

Urine from cancer patients with weight loss showed the presence of an antigen of M(r) 24,000 detected with a monoclonal antibody formed by fusion of splenocytes from mice with cancer cachexia. The antigen was not present in the urine of normal subjects, patients with weight loss from conditions other than cancer or from cancer patients who were weight stable or with low weight loss (1 kg month(-1)). The antigen was present in the urine from subjects with carcinomas of the pancreas, breast, lung and ovary. The antigen was purified from urine using a combination of affinity chromatography with the mouse monoclonal antibody and reversed-phase high-performance liquid chromotography (HPLC). This procedure gave a 200,000-fold purification of the protein over that in the original urine extract and the material isolated was homogeneous, as determined by silver staining of gels. The N-terminal amino acid sequence showed no homology with any of the recognized cytokines. Administration of this material to mice caused a significant (P<0.005) reduction in body weight when compared with a control group receiving material purified in the same way from the urine of a normal subject. Weight loss occurred without a reduction in food and water intake and was prevented by prior administration of the mouse monoclonal antibody. Body composition analysis showed a decrease in both fat and non-fat carcass mass without a change in water content. The effects on body composition were reversed in mice treated with the monoclonal antibody. There was a decrease in protein synthesis and an increase in degradation in skeletal muscle. Protein degradation was associated with an increased prostaglandin E2 (PGE2) release. Both protein degradation and PGE2 release were significantly reduced in mice pretreated with the monoclonal antibody. These results show that the material of M(r) 24,000 present in the urine of cachectic cancer patients is capable of producing a syndrome of cachexia in mice.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9303359      PMCID: PMC2228019          DOI: 10.1038/bjc.1997.433

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  37 in total

Review 1.  Cachexia, the metabolic component of neoplastic diseases.

Authors:  G Costa
Journal:  Cancer Res       Date:  1977-07       Impact factor: 12.701

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Tumor necrosis factor in children with malignancies.

Authors:  U M Saarinen; E K Koskelo; A M Teppo; M A Siimes
Journal:  Cancer Res       Date:  1990-02-01       Impact factor: 12.701

4.  Parabiotic transfer of cancer anorexia/cachexia in male rats.

Authors:  J A Norton; J F Moley; M V Green; R E Carson; S D Morrison
Journal:  Cancer Res       Date:  1985-11       Impact factor: 12.701

5.  Serum amino acids in weight-losing patients with cancer and tuberculosis.

Authors:  L Levin; W Gevers; L Jardine; F J De Guel; E J Duncan
Journal:  Eur J Cancer Clin Oncol       Date:  1983-06

6.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group.

Authors:  W D Dewys; C Begg; P T Lavin; P R Band; J M Bennett; J R Bertino; M H Cohen; H O Douglass; P F Engstrom; E Z Ezdinli; J Horton; G J Johnson; C G Moertel; M M Oken; C Perlia; C Rosenbaum; M N Silverstein; R T Skeel; R W Sponzo; D C Tormey
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

7.  Tumors secreting human TNF/cachectin induce cachexia in mice.

Authors:  A Oliff; D Defeo-Jones; M Boyer; D Martinez; D Kiefer; G Vuocolo; A Wolfe; S H Socher
Journal:  Cell       Date:  1987-08-14       Impact factor: 41.582

8.  Elevated energy expenditure in cancer patients with solid tumours.

Authors:  A Hyltander; C Drott; U Körner; R Sandström; K Lundholm
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

9.  Purification and characterization of a lipid-mobilizing factor associated with cachexia-inducing tumors in mice and humans.

Authors:  T M McDevitt; P T Todorov; S A Beck; S H Khan; M J Tisdale
Journal:  Cancer Res       Date:  1995-04-01       Impact factor: 12.701

10.  Characterization of mice bearing subclones of colon 26 adenocarcinoma disqualifies interleukin-6 as the sole inducer of cachexia.

Authors:  K Soda; M Kawakami; A Kashii; M Miyata
Journal:  Jpn J Cancer Res       Date:  1994-11
View more
  29 in total

Review 1.  A review of the drug treatment of cachexia associated with cancer.

Authors:  B Gagnon; E Bruera
Journal:  Drugs       Date:  1998-05       Impact factor: 9.546

2.  A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer.

Authors:  M L Williams; P Bhargava; I Cherrouk; J L Marshall; D A Flockhart; I W Wainer
Journal:  Br J Clin Pharmacol       Date:  2000-05       Impact factor: 4.335

3.  A neural survival factor is a candidate oncogene in breast cancer.

Authors:  Dale Porter; Stanislawa Weremowicz; Koei Chin; Pankaj Seth; Aparna Keshaviah; Jaana Lahti-Domenici; Young Kyung Bae; Constance L Monitto; Ana Merlos-Suarez; Jennifer Chan; Christine M Hulette; Andrea Richardson; Cynthia C Morton; Jeffrey Marks; Mabel Duyao; Ralph Hruban; Edward Gabrielson; Rebecca Gelman; Kornelia Polyak
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-02       Impact factor: 11.205

Review 4.  Cancer cachexia.

Authors:  Michael J Tisdale
Journal:  Langenbecks Arch Surg       Date:  2004-05-28       Impact factor: 3.445

5.  Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass.

Authors:  Kunihiro Sakuma; Akihiko Yamaguchi
Journal:  J Cachexia Sarcopenia Muscle       Date:  2012-01-12       Impact factor: 12.910

6.  Attenuation of muscle atrophy by an N-terminal peptide of the receptor for proteolysis-inducing factor (PIF).

Authors:  K A Mirza; S M Wyke; M J Tisdale
Journal:  Br J Cancer       Date:  2011-06-14       Impact factor: 7.640

7.  The presence of the proteolysis-inducing factor in urine does not predict the malignancy of a pancreatic tumour.

Authors:  Niels Teich; Jörg Kleeff; Herbert Lochs; Joachim Mössner; Volker Keim; Helmut Friess; Johann Ockenga
Journal:  BMC Gastroenterol       Date:  2005-06-21       Impact factor: 3.067

8.  Development of an in-vitro model system to investigate the mechanism of muscle protein catabolism induced by proteolysis-inducing factor.

Authors:  M C C Gomes-Marcondes; H J Smith; J C Cooper; M J Tisdale
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

9.  Cancer cachexia: impact, mechanisms and emerging treatments.

Authors:  Vanessa C Vaughan; Peter Martin; Paul A Lewandowski
Journal:  J Cachexia Sarcopenia Muscle       Date:  2012-10-25       Impact factor: 12.910

10.  Metabolic and morphological alterations induced by proteolysis-inducing factor from Walker tumour-bearing rats in C2C12 myotubes.

Authors:  Claudia L Yano; Gislaine Ventrucci; William N Field; Michael J Tisdale; Maria Cristina C Gomes-Marcondes
Journal:  BMC Cancer       Date:  2008-01-28       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.